5 Four of these had clinical and biochemical improvement, with sustained graft function. In Nachman et al.’s series, the majority of patients received Cyclophosphamide

(12/16) as treatment, with 11/16 attaining a complete remission.4 The duration of Cyclophosphamide treatment was not stated. The use of plasma exchange is well documented in AAV-affecting native kidneys and while its use in the transplant recurrence setting lacks prospective data it is likely that many clinicians are using it particularly as for native AAV when there is pulmonary involvement or high ANCA titres. The monoclonal anti-CD20 antibody, Rituximab, is widely used as an alternative to Cyclophosphamide in inducing remission in AAV-affecting native kidney disease and its use in treating recurrent Selumetinib vasculitis in the transplant setting is emerging as an alternative to Cyclophosphamide. The ideal time to transplant patients who have ESRD from AAV is not yet clear, although there is general consensus that there should be clinical remission at the time of transplantation. Little et al.’s series from European vasculitis group EUVAS showed that the strongest predictor of death was transplantation <1 year post-vasculitis remission.9 ANCA positivity at the time of transplantation did not increase the risk of relapse or graft loss, which is in concordance with the series of Nachman et al.4 We report a case of recurrent AAV in the renal allograft,

successfully treated with Cyclophosphamide, plasma exchange and increased-dose Prednisolone. Kidney transplantation is a safe and viable option for those with ESRD secondary KPT-330 concentration to AAV. Overall, graft survival is excellent, and comparable with transplantation for other causes of ESRD. Relapse rates vary, but are perhaps lower

with modern immunosuppression and while there are several emerging potential treatment options for relapse at this stage, including the use of plasma exchange and Rituximab, Cyclophosphamide remains the cornerstone of therapy. None. “
“Metabolic syndrome (MS) is associated with higher mortality and morbidity in the general population. However, the effect of MS and its individual components on clinical DNA ligase outcomes in non-diabetic peritoneal dialysis (PD) patients has not been widely studied in India. Our aim was to study the prevalence of MS in non-diabetic PD patients who were on PD for at least 3 months and to analyze the influence of MS and its individual components on clinical outcomes of these patients on subsequent follow up. We prospectively included 163 non-diabetic PD patients (mean age 45.1 ± 16.2 years, 104 male). MS was defined using the modified National Cholesterol Education Programme (ATP III) criteria. Outcomes of patients with and without MS were compared. Of the 163 non-diabetic PD patients, 84 (51.5%) patients had MS. The mean follow up duration was 24.0 ± 14.0 patient months. Patients with MS had significantly greater body mass index (P = 0.007), Systolic BP (P = 0.